Table 1.
Patient's demographics and baseline ocular findings.
| Characteristics | Value |
|---|---|
| No. of patients | 26 |
| No. of eyes | 29 |
| Age, mean ± SD (years) | 58.3 ± 9.3 |
| Sex, male/female (%) | 12/14 (46/54) |
| Type of diabetes, type 1/type 2 (%) | 2/24 (8/92) |
| Hemoglobin A1C, mean ± SD (%) | 8.9 ± 1.7 |
| Hypertension (%) | 11 (42) |
| Type of diabetic retinopathy, NPDR/PDR (%) | 18/11 (62/38) |
| Lens status, phakic/pseudophakic (%) | 17/12 (59/41) |
| Panretinal photocoagulation (%) | 21 (72) |
| No. of prior intravitreal bevacizumab injections, mean ± SD | 4.4 ± 2.1 |
| Duration of treatment for intravitreal bevacizumab injection, mean ± SD (month) | 6.4 ± 4.8 |
| Best-corrected visual acuity (log MAR), mean ± SD | 0.73 ± 0.42 |
| Central subfield thickness, mean ± SD (μm) | 592.6 ± 180.5 |
SD = standard deviation; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative retinopathy; logMAR = logarithm of the minimal angle of resolution.